"'Fighter drugs' and their misuse by armed non-state actors represent an emerging dimension of transnational security threats." Comment.

"Fighter drugs" — pharmaceutical opioids consumed by combatants to suppress fatigue, fear and pain — have moved from medicine cabinets into conflict theatres. Their diversion by armed non-state actors converts a public-health and trade-regulation issue into a hard security concern, and the statement is largely valid.

Why fighter drugs differ from conventional drug abuse

• Tramadol earned the "fighter drug" label after reports of use by ISIS combatants to counter fatigue and fear — demand driven by combat endurance, not recreation [1].
• Legally it is a psychotropic substance, notified under the NDPS Act, 1985 in 2018, with export restricted under Section 8(c) [2]. Its diversion is a regulatory breach, not street-level smuggling.
• Volumes are war-scale: Operation Vajra yielded 12 crore tablets of 250 mg strength, about 30 metric tons [1].

Transnational security dimensions

• Financing: bulk opioid profits sustain the logistics and arms purchases of non-state actors — the narco-terror nexus.
• Routing: the consignment was declared for Guinea-Bissau but intended for diversion to Libya, mapping a West Africa transshipment corridor into conflict zones [1]. Coordination with the INCB and Guinea-Bissau authorities exposed the misdeclared destination [1].
• Channel abuse: legitimate pharma export documentation and warehousing served as cover, revealing EXIM oversight gaps.

India's exposure and institutional response

• As a major pharmaceutical exporter, India faces strategic and reputational risk from such diversion.
• The Central Bureau of Narcotics (Department of Revenue, Ministry of Finance) regulates international trade in narcotic drugs, psychotropic substances and precursors under UN conventions and the NDPS Act [3].
• Enforcement is multi-agency and multi-city — CBN with DRI Bengaluru and Kochi, seizure in Delhi, three arrests [1].

Fighter drugs thus sit at the junction of trade regulation, public health and armed conflict. The way forward lies in end-use verification and digital track-and-trace for opioid exports, real-time CBN–DRI–Customs data sharing, and deeper INCB engagement. Operation Vajra shows that preventive intelligence, backed by India's UN convention obligations, can secure both global peace and India's pharmaceutical credibility.